← Clinical Trial Results
Acute Myocardial Infarction Randomized Trial Prevention NCT01740479

COMPLETE: Complete Statistical Analysis of Complete Revascularization in STEMI

An independent statistical review of the COMPLETE trial evaluating a complete revascularization strategy versus culprit-only revascularization for patients with multivessel disease after early PCI for STEMI.

ClinicalTrials.gov record: NCT01740479
Scope of this record

This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.

1. Trial at a Glance

COMPLETE was a randomized, parallel-group clinical trial evaluating complete revascularization compared with culprit-only revascularization after early PCI for STEMI in patients with multivessel disease.

4042
Enrollment
2
Study arms
2013-02-01
Start date
2019-06-07
Primary completion
FeatureCOMPLETE
NCT IDNCT01740479
StatusCompleted
PhaseNA
AllocationRandomized
Design modelParallel
MaskingSingle
Primary purposePrevention
Lead sponsorPopulation Health Research Institute

2. Clinical Question

Population

Patients with acute myocardial infarction and coronary artery disease enrolled after early PCI for STEMI with multivessel disease.

Intervention

Complete Revascularization Strategy (procedure).

Comparator

Culprit-only revascularization.

Primary question

Does complete revascularization improve composite cardiovascular outcomes compared with culprit-only treatment?

3. Trial Design

Design
Randomized parallel-group trial.
Arms
Two treatment groups.
Enrollment
4042 participants.
Study status
Completed.

4. Endpoints

EndpointTime frameDescription
Composite of cardiovascular death or new myocardial infarctionOver duration of follow-up (average of approximately 4 years)Co-primary outcome: CV death or new MI
Composite of cardiovascular death, new myocardial infarction or ischemia-driven revascularizationOver duration of follow-up (average of approximately 4 years)Co-primary outcome: CV death, new MI or IDR

5. Planned Analysis

The ClinicalTrials.gov record identifies the primary outcomes but does not report posted statistical analyses or outcome estimates. The registry does not report formal endpoint results for the co-primary outcomes.

For composite cardiovascular time-to-event outcomes of this type, a typical analysis evaluates time from randomization to the first occurrence of any component event. Statistical methods commonly include survival analysis approaches such as Kaplan-Meier estimation for event-free probability over time and regression models such as Cox proportional-hazards models to estimate relative treatment effects.

How composite endpoints are interpreted

A composite endpoint combines multiple clinically relevant events into a single outcome. The analysis generally counts the first qualifying event experienced by each participant. Interpretation requires understanding which components drive the overall result because components may differ in clinical importance and frequency.

6. Statistical Methodology

Randomization

Randomization is designed to create comparable treatment groups at baseline, allowing differences in outcomes to be attributed more confidently to the assigned strategies rather than measured and unmeasured baseline differences.

Time-to-event analysis

Because cardiovascular death, myocardial infarction, and revascularization occur over follow-up time, survival analysis methods are appropriate. These methods account for participants who have not experienced an event by the end of observation or who have incomplete follow-up.

Survival function: S(t) = P(T > t)

The survival function represents the probability that an event has not occurred by time t.

Hazard ratios

A Cox proportional-hazards model is commonly used for randomized cardiovascular trials because it compares event rates over time while accounting for follow-up duration.

Clinical Biostats interpretation

A hazard ratio below 1 would indicate a lower estimated instantaneous event rate in the intervention group relative to the comparator. It would not represent the percentage of patients prevented from having an event, and it would not describe the experience of every individual participant.

Confidence intervals describe uncertainty around an estimate. A narrow interval suggests greater precision than a wide interval, while a p-value addresses compatibility with a statistical hypothesis and does not measure the size or importance of an effect.

7. Statistical Methods Explained

Why use a composite endpoint?

A composite endpoint can increase statistical efficiency by counting multiple clinically relevant outcomes together, particularly when individual events are less frequent.

Why does time-to-event analysis matter?

Participants are followed for different lengths of time. Survival methods allow researchers to use available follow-up information without requiring every participant to experience an event.

What does randomization accomplish?

Randomization balances known and unknown prognostic factors between groups on average, supporting an unbiased comparison of assigned strategies.

Why analyze cardiovascular death and myocardial infarction together?

The combined endpoint reflects a broader cardiovascular outcome measure, but interpretation requires consideration of the contribution of each component.

Why are confidence intervals important?

An estimate alone does not show how much uncertainty surrounds the finding. Confidence intervals provide a range of values compatible with the observed data under the statistical model.

8. Limitations

9. Why This Trial Matters Statistically

COMPLETE is a useful statistical teaching example because it illustrates several important principles in cardiovascular clinical trials.

ConceptApplication
RandomizationComparison of complete revascularization and culprit-only strategies
Composite endpointsCombining cardiovascular death, myocardial infarction, and ischemia-driven revascularization outcomes
Time-to-event analysisEvaluation of outcomes occurring over follow-up
Clinical interpretationSeparating statistical estimates from individual patient outcomes

10. Sources